Open in interactive viewer → charts, metric popovers & call review

MDB Capital Moves the Payout to 2027 and Turns Its Scale-Up Into a Spin-Out

Down 57% in 90 days with $8.3 million of operating cash, MDB reframes four 'value inflection' assets as a survival plan — and quietly pushes the distribution promise out a year.
MDBH · Earnings Call · 2026-11-17

The tone versus the tape

Chris Marlett opened the third-quarter 2026 webcast by conceding “the market has been a bit tumultuous and a lot of uncertainty out there” — Christopher Marlett, Unknown · 2026-11-17, then declared himself decidedly upbeat. The tape disagrees. MDBH has fallen 57% in the last 90 trading days on a single unbroken 17-week decline, closing the period 58.6% below its mid-July high and 88.7% under the $12.82 peak set in February 2024. For a $15 million market-cap holding company, that is not a wobble; it is a repricing of the entire model. The more honest line came at the very end: “we're excited. We're also -- we're stressed as well. I mean, the market has not been kind to these companies and to us.” — Christopher Marlett, Unknown · 2026-11-17 That gap — four imminent breakthroughs narrated over a stock making fresh lows — is the report.

Four assets, one word: inflection

Two quarters ago the company's top keyword was value inflection point. This quarter it has collapsed into a single repeated phrase, inflection point, applied indiscriminately to all four holdings: Public Ventures (the self-clearing broker-dealer), PatentVest (the Arizona-scoped IP firm), eXoZymes (cell-free synthetic biology) and Paulex Bio (beta-cell regeneration). What is genuinely new is the commercial vocabulary underneath that slogan. The fresh high-momentum terms this quarter are concrete: nutritional supplement, patent applications, beta cell, synthetic biology, new compounds. That is the language of products shipping, not platforms being built. Marlett's patent pitch is unusually specific: PatentVest can now “take an invention and put it into a legal and business context, instantly create those claims” — Christopher Marlett, Unknown · 2026-11-17 — a claimed one-day cycle where the industry takes months, and a throughput claim of 1,000 applications a year against eXoZymes' own need for roughly 100. The older framing has quietly aged out. ABS law firm and practice of law — the scaffolding of the 2025 PatentVest narrative — are gone, replaced by IP law as a product. So too with the portfolio's public reference points. Buda Juice and HeartBeam, top-30 company keywords as recently as late 2025, now appear only as rhetorical props — proof that good operators get punished anyway. That is a telling demotion: the marks that used to validate the model are now evidence the market is broken.

The promise that moved a year

Here is the tension that matters. In August 2025, asked about harvesting the portfolio into shareholders' hands, Marlett said “my sense is that 2026 is the right year for that” — Chris Marlett, Chief Financial Officer · 2025-08-27. On the same call, George Schuman walked through the holdings and concluded “hopefully, in 2026, I think that's kind of the year makes sense” — George Schuman, Head of Community Development · 2025-08-27. Twelve months later the language is unchanged in spirit and a year later in fact:

We want to deliver these assets out. And I think that we expect to have distributions in 2027 of those assets to the shareholders.

Christopher Marlett, Unknown · 2026-11-17
The second reversal is structural. The 2025 story was deliberate scale-up — a clearing firm, a trained analyst bench in Latin America, operating expense rising from roughly $5 million to $10 million a year, justified by fee income. The 2026 story is the exact inverse: “we need to run a much leaner shop, and we'll be cutting expenses while we're also liberating ourselves of current cash OpEx by funding and partnering Public Ventures and PatentVest going forward” — Christopher Marlett, Unknown · 2026-11-17. Public Ventures, a recurring top-tier company theme for two straight quarters, is now an asset to be partnered away rather than scaled. That is a strategic retreat dressed as an evolution — and it rhymes with cost reduction plan and cost optimization efforts, both of which rank among the market's better-performing themes over 360 and 90 days respectively. Investors are rewarding cost discipline broadly; MDB is now riding that wave under duress rather than by design.

What the cash says

The financials make the strategy legible. Operating income was a $6 million loss in the latest reported quarter against $6 million of effective SG&A, and free cash flow excluding stock comp ran at negative $5 million. Against roughly $8.3 million of stated operating cash, that is a runway measured in a couple of quarters, not years. Fee income of $4.2 million over nine months, per Marlett, ameliorated our burn — ameliorated, not covered. The balance sheet is the one unalloyed positive: liabilities at just 2.2% of assets means nothing is forcing a fire sale. But time is the binding constraint, and the company's own history says the answer to time pressure has been dilution. In November 2025 the CEO was candid about that: “any time you buy a public venture company, they're going to need to raise more capital and we as shareholders are going to be diluted” — Christopher Marlett, CEO · 2025-11-20.

The question to watch

The bull case is real and mathematically levered: under 11 million shares outstanding and a $15 million market cap against stakes in four companies, any single win is a multiple. The cannabinoid tangent — “there's one cannabinoid that's been approved that is doing over $1 billion in sales and got bought for about $7 billion” — Christopher Marlett, Unknown · 2026-11-17 — is the sort of asymmetry that justifies the structure on paper, and the GLP 1 angling around Paulex's beta-cell drug is the right adjacency to a market that keeps rewarding obesity-adjacent assets. But the inflection argument has been made for at least three consecutive calls, and each time the receipts have slipped a quarter. The recurring complaint about the market environment and the plight of the small company is not new information — it is a fixed feature of the genre, and it has been audible since at least November 2025, when Marlett identified the microcap market as the number one reason for the stock's discount. What would change the story now is not another platform description but two signed transactions: a Public Ventures partner and a PatentVest financing. Until those land, 2027 is a date, not a plan, and the access to capital problem remains the company's own.